Raiffeisen Bank International AG Boosts Position in BioNTech SE Sponsored ADR $BNTX

Raiffeisen Bank International AG grew its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 5.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,500 shares of the company’s stock after acquiring an additional 500 shares during the period. Raiffeisen Bank International AG’s holdings in BioNTech were worth $1,100,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its position in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock valued at $108,859,000 after purchasing an additional 581,173 shares during the period. Bank of New York Mellon Corp raised its stake in shares of BioNTech by 58.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after buying an additional 410,351 shares during the last quarter. Aberdeen Group plc raised its stake in shares of BioNTech by 87.2% during the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after buying an additional 336,260 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of BioNTech by 643.7% in the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock valued at $58,747,000 after buying an additional 558,389 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of BioNTech by 252.5% in the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after buying an additional 390,360 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

BioNTech stock opened at $102.53 on Wednesday. The stock has a market capitalization of $24.65 billion, a P/E ratio of -64.08 and a beta of 1.54. The company’s fifty day moving average price is $102.92 and its 200 day moving average price is $104.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $129.27.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the prior year, the company posted $0.81 earnings per share. The business’s revenue was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. UBS Group lifted their price target on BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. HC Wainwright raised their price objective on shares of BioNTech from $136.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Bank of America cut their target price on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an “overweight” rating in a report on Tuesday, August 5th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Monday. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.20.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.